Ongoing HIV dissemination during HAART

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Plasma HIV RNA first-week decrease with four-drug combination therapy.
Figure 2: HIV RNA decay rate constants for one-, three- and five-drug regimens; the means of individual decay rate constants were calculated for 16, 15 and 9 patients, respectively.
Figure 3: Linking HIV production to immune activation.
Figure 4: HIV RNA decrease with a four-drug combination therapy.


  1. 1

    Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).

  2. 2

    Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995).

  3. 3

    Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582–1586 (1996).

  4. 4

    Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188–191 (1997).

  5. 5

    Grossman, Z., Feinberg, M., Kuznetsov, V., Dimitrov, D. & Paul, W. HIV infection: how effective is drug combination treatment? Immunol. Today 19, 528–532 (1998).

  6. 6

    Kim, S., Byrn, R., Groopman, J. & Baltimore, D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63, 3708–3713 (1989).

  7. 7

    Dimitrov, D.S. et al. Quantitation of HIV-1 infection kinetics. J. Virol. 67, 2182–2190 (1993).

  8. 8

    Cavert, W. et al. Kinetics of response in lymphoid tissues to anti-retroviral therapy of HIV-1 infection. Science 276, 960–964 (1997); erratum: 276, 1321 (1997).

  9. 9

    Mueller, B.U. et al. Individual prognoses of long-term responses to anti-retroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 12, F191–F196 (1998).

  10. 10

    Igarashi, T. et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211–216 (1999).

  11. 11

    Zhang, L. et al. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J. Virol. 73, 855–856(1999).

  12. 12

    Grossman, Z., Feinberg, M.B. & Paul, W.E. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc. Natl. Acad. Sci. USA 95, 6314–6319 (1998).

  13. 13

    Grossman, Z., Herberman, R.B. & Dimitrov, D. T Cell turnover in SIV infection. Science 284, 555a–555b (1999).

  14. 14

    Cheynier, R. et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78, 373–387 (1994).

  15. 15

    Cheynier, R. et al. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nature Med. 4, 421–427 (1998).

  16. 16

    Autran, B. et al. Positive effects of combined anti-retroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112–116 (1997).

  17. 17

    Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).

  18. 18

    Harrigan, P.R., Whaley, M. & Montaner, J.S.G. Rate of HIV-1 RNA rebound upon stopping anti-retroviral therapy. AIDS 13, F59–F62(1999).

  19. 19

    Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy. N. Engl. J. Med. 340, 1605–1613 (1999).

  20. 20

    Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy. N. Engl. J. Med. 340, 1614–1622 (1999).

  21. 21

    Bucy, R.P. Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. AIDS Res. Hum. Retroviruses 15, 223–227 (1999).

  22. 22

    Grossman, Z. and Herberman, R.B. T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nature Med. 3, 486–490 (1997).

  23. 23

    Reijers, M.H. et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam duration of anti-retroviral medication (ADAM) study. Lancet 352, 185–190 (1998).

  24. 24

    Pialoux, G. et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N. Engl. J. Med. 339, 1269–1276 (1998).

  25. 25

    Havlir, D.V. et al. Maintenance anti-retroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS clinical trials group study 343 team. N. Engl. J. Med. 339, 1261–1268 (1998).

  26. 26

    Bonhoeffer, S., May, R.M., Shaw, G.M. & Nowak, M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94, 6971–6976 (1997).

Download references


We thank S. Danner, J. Metcalf, B. Mueller, P.A. Pizzo, G.-J. Waverling and C. Yoder for their contribution to the clinical trials and for making patient data available for analysis. We thank S.Livnat for reading and improving the manuscript.

Author information

Correspondence to Zvi Grossman.

Rights and permissions

Reprints and Permissions

About this article

Further reading